...
首页> 外文期刊>Breast care >Influence of Orally Administered Probiotic Lactobacillus Strains on Vaginal Microbiota in Women with Breast Cancer during Chemotherapy: A Randomized Placebo-Controlled Double-Blinded Pilot Study
【24h】

Influence of Orally Administered Probiotic Lactobacillus Strains on Vaginal Microbiota in Women with Breast Cancer during Chemotherapy: A Randomized Placebo-Controlled Double-Blinded Pilot Study

机译:口服给药益生菌菌株对化疗过程中乳腺癌阴道微生物症的影响:随机安慰剂对双盲试验研究

获取原文
获取原文并翻译 | 示例

摘要

Background: Due to chemotherapy and estrogen deprivation therapy, genitourinary syndrome of menopause is a common condition in breast cancer patients. We aimed to determine the effect of an orally administered Lactobacillus preparation on the vaginal microbiota in breast cancer patients. Methods: Postmenopausal breast cancer patients receiving chemotherapy, with vaginal atrophy and an intermediate vaginal microbiota (Nugent score 4-6), were either randomized to the intervention group receiving probiotic capsules of 4 Lactobacillus species or to the control group receiving placebo twice daily for 2 weeks. Consecutive vaginal swabs were taken at baseline, 1 day after administration of the last capsule (follow-up 1), and after 1 week (follow-up 2) in 22 patients (11 vs. 11). Results: We observed a positive influence on the vaginal microbiota in 7/11 (63%) women in the intervention group, and 4/11 (36%) women in the control group. There was a shift in Nugent score towards normal microbiota levels in the intervention group (-1.3 at follow-up 1, -0.45 at follow-up 2) and a significant deterioration of the Nugent score in the control group (+0.4 at follow-up 1, +2.5 at follow-up 2). Conclusion: The orally administered Lactobacillus preparation has the potential to improve the vaginal microbiota in women undergoing chemotherapy for breast cancer. (C) 2017 The Author(s). Published by S. Karger GmbH, Freiburg
机译:背景:由于化疗和雌激素剥夺疗法,更年期的泌尿病综合征是乳腺癌患者的常见条件。我们的旨在确定口服乳杆菌制剂对乳腺癌患者阴道微生物的影响。方法:治疗后医疗乳腺癌患者接受化疗,具​​有阴道萎缩和中间阴道微生物群(污染得分4-6),可随机分配到接受4乳杆菌物种的益生菌胶囊或对照组每天接受安慰剂两次治疗组周。连续的阴道拭子在基线上拍摄,在给予最后一次胶囊(随访1)后1天,22例患者(11例)后1周(随访2)。结果:我们观察了对照组7/11(63%)妇女的阴道微生物群,4/11(36%)妇女在对照组中的阳性影响。在干预组的常规微生物群水平中,苦难评分的变化(-1.3在随访1,-0.45时2),对照组苦难评分的显着恶化(+0.4在以下 - 随访2)上升1,+2.5)。结论:口服给药的乳杆菌制剂具有改善乳腺癌化疗的女性中阴道微生物的潜力。 (c)2017年作者。由弗赖堡的S. Karger GmbH出版

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号